Gastroenterology
Volume 130, Issue 3 , Pages 632-638 , March 2006

Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response

  • Sanaa M. Kamal

      Affiliations

    • Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • Department of Gastroenterology and Hepatology, University of Freiburg, Freiburg, Germany
    • Corresponding Author InformationAddress requests for reprints to: Sanaa M. Kamal, MD, Liver Disease Center, Beth Israel Deaconess Medical Center, 4 Blackfan Circle, Boston, Massachusetts 02115.fax:
    • ,
  • Amr E. Fouly

      Affiliations

    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • ,
  • Refaat R. Kamel

      Affiliations

    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • ,
  • Bridgette Hockenjos

      Affiliations

    • Department of Gastroenterology and Hepatology, University of Freiburg, Freiburg, Germany
    • ,
  • Ahmed Al Tawil

      Affiliations

    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • ,
  • Khalifa E. Khalifa

      Affiliations

    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • ,
  • Qi He

      Affiliations

    • Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • ,
  • Margaret J. Koziel

      Affiliations

    • Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • ,
  • Khairy M. El Naggar

      Affiliations

    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • ,
  • Jens Rasenack

      Affiliations

    • Department of Gastroenterology and Hepatology, University of Freiburg, Freiburg, Germany
    • ,
  • Nezam H. Afdhal

      Affiliations

    • Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Received 23 August 2005 ,Accepted 21 December 2005.

  • Image Result

    Study design flow chart. Patients were randomized after an 8-week observation period. Patients who did not resolve spontaneously by week 8 were randomized to start treatment immediately at week 8 (gro

    Study design flow chart. Patients were randomized after an 8-week observation period. Patients who did not resolve spontaneously by week 8 were randomized to start treatment immediately at week 8 (group A), week 12 (group B), or week 20 (group C). Patients who resolved spontaneously or withdrew prematurely from treatment were encouraged to return for follow-up.

  • Image Result
    SVR rates according to genotype. The x-axis represents the different genotypes. The percent of patients showing SVR is represented on the y-axis. Black bars represent group A patients who started ther

    SVR rates according to genotype. The x-axis represents the different genotypes. The percent of patients showing SVR is represented on the y-axis. Black bars represent group A patients who started therapy at week 8. White bars represent group B patients who started treatment at week 12. Gray bars represent group C patients who started treatment at week 20.

 Supported by the National Institutes of Allergy and Infectious Diseases (grant nos. R21 AI054887, R21 AI41563, and R01 AI068966); Fulbright Commission, USA (TEMPUS: grant no. IMG 04-E.G. 1096); Alexander von Humboldt Foundation, Germany; and International Society of Infectious Diseases, USA (grant no. RF-9641).

PII: S0016-5085(06)00061-8

doi: 10.1053/j.gastro.2006.01.034

Gastroenterology
Volume 130, Issue 3 , Pages 632-638 , March 2006

Article Tools

* Image Usage & Resolution